合并肺纤维化与肺气肿的临床结局及急性加重发生率
这项多中心前瞻性队列研究纳入1016例特发性间质性肺炎(IIP)或慢阻肺患者,按国际分类标准以CT视觉评估肺气肿≥5%定义CPFE。528例IIP中92例(17.4%)为CPFE,其5年生存率显著低于非CPFE的IIP患者和慢阻肺患者,且急性加重率更高,调整混杂因素后CPFE仍独立关联死亡风险升高。
要点
- CT视觉评估肺气肿≥5%可识别出预后较差的CPFE临床表型。
- CPFE患者5年生存率51.4%,显著低于非CPFE的IIP和慢阻肺患者。
- CPFE患者急性加重率显著高于非CPFE的IIP患者。
核心结论
- 以肺气肿≥5%为阈值的视觉评估可有效识别CPFE患者,该表型以生存差和急性加重发生率高为特征。
- 研究结果验证了国际分类标准,并强调对该高危人群需加强监测和个体化管理。
研究设计与样本
- 多中心前瞻性队列研究,2013至2016年在29家日本医院纳入1016例IIP或慢阻肺患者,随访5年。
- CPFE定义为IIP患者CT视觉评估肺气肿≥5%,依据国际分类标准。
主要发现
- 528例IIP患者中92例(17.4%)为CPFE。
- CPFE患者5年生存率51.4%,非CPFE的IIP患者为63.1%(p=0.026),慢阻肺患者为84.0%(p<0.001)。
- 调整包括IIP亚型在内的协变量后,CPFE在IIP患者中仍独立关联死亡风险升高(HR 1.85[95%CI 1.27-2.69],p<0.001)。
- CPFE患者急性加重率显著高于非CPFE的IIP患者(p<0.001)。
- CPFE的预后影响在特发性肺纤维化(IPF)患者中最显著,CPFE/IPF患者结局最差。
关键数值与推荐
- CPFE诊断阈值:IIP患者CT视觉评估肺气肿≥5%。
- CPFE患者5年生存率51.4%,非CPFE的IIP患者63.1%,慢阻肺患者84.0%。
- CPFE关联死亡风险的HR为1.85(95%CI 1.27-2.69,p<0.001)。
临床怎么用
- 对IIP患者应常规行CT视觉评估肺气肿范围,≥5%时按CPFE管理并加强随访。
- CPFE患者尤其合并IPF者需警惕急性加重和不良生存,考虑更密切监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Combined pulmonary fibrosis and emphysema (CPFE) is characterized by coexisting upper-zone emphysema and lower-zone fibrosis, but standardized diagnostic criteria and clinical outcomes remain poorly defined. This study aimed to evaluate survival, acute exacerbation incidence, and disease progression in CPFE patients using international classification criteria with visual assessment of emphysema extent. METHODS: This multicentre prospective cohort study at 29 Japanese hospitals enrolled 1016 patients with idiopathic interstitial pneumonias (IIPs) or chronic obstructive pulmonary disease (COPD) between 2013 and 2016. CPFE was defined as ≥ 5% emphysema determined by visual assessment of CT scans for IIP patients, according to international classification criteria. Patients were followed for 5 years. RESULTS: Among 528 IIP patients, 92 (17.4%) had CPFE. CPFE patients showed a significantly worse 5-year survival compared with non-CPFE IIP patients (51.4% vs. 63.1%, p = 0.026) and COPD patients (51.4% vs. 84.0%, p < 0.001). After adjustment for covariates including IIP subtype, CPFE remained independently associated with increased mortality among IIP patients (HR of 1.85 [95% CI, 1.27-2.69], p < 0.001). CPFE patients also had a significantly higher acute exacerbation rate than did non-CPFE IIP patients (p < 0.001). The prognostic impact of CPFE was most pronounced in patients with idiopathic pulmonary fibrosis (IPF), with CPFE/IPF patients showing the worst outcomes. CONCLUSION: Visual assessment with a ≥ 5% emphysema threshold effectively identified CPFE patients with a distinct clinical phenotype characterized by poor survival and an increased acute exacerbation incidence. These findings validate international classification criteria and emphasize the need for enhanced surveillance and tailored management strategies for this high-risk population.
引用
- Tsubouchi, Kotetsu, Takano, et al. Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema. Respirology. 2026. PMID: 42417564. doi:10.1002/resp.70285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。